The rise in aging population, sedentary lifestyles and increasing obesity are increasingly common, This increasing the concerns of diabetes worldwide. The Center for Disease Control (CDC) has estimated that, 9.3% of the US population are suffering with diabetes, together with an estimated 8.1 million who are undiagnosed. This costed $245 billion per annum or approximately $500,000 every minute in 2012, in US.
The significant success of the Diabetes Research Institute, at the University of Miami Miller School of Medicine proclaimed that as a result of implantation of islet cells within a biological scaffold has helped their first clinical trials patients to stop the use of insulin.
Companies Developing Treatment for Diabetes:
With the help of regenerative medicine, the below mentioned corporations are discovering stem cell-based therapy as a practicable therapy for people having diabetes.
1. ViaCyte – San Diego, US
In February 2016, San Diego based ViaCyte acquired an exclusive license to “BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.” The news positioned ViaCyte as a leader in stem cell therapeutics for the treatment of Type 1 and 2 diabetes. BetaLogics and ViaCyte have individualistically explored the stem cell-derived therapy for diabetes.
The product segregates stem cells into pancreatic beta cell precursors (PEC-01) and hypodermically transplants them into person suffering diabetes using a retrievable medical device. After the maturation of the implanted cells into endocrine cells which can potentially secrete insulin and other hormones to regulate the blood glucose levels.
2. Sernova – Canada
In September 2015, the exclusive rights of patent -pending technology by researcher at the University Health Network in Canada was acquired by Sernova Corporation, with the authorization giving them the ability to turn stem cells into glucose-responsive therapeutic cells.
3. Betalin Therapeutics – Israel
Betalin Therapeutics, Ltd. is developing the Engineered Micro Pancreas (EMP), to implant pancreatic cells, which comprise insulin-producing ability to reinstate the body’s basic insulin production capacity. This miniature pancreas is entrenched in the patients’ body hypo dermally with the help of local anesthesia.
Betalin has attained the technology that is grounded on the principle that for proper functioning of the beta cells, it is essential to offer a suitable stromal microenvironment. In phase I, the platform technology is used for the creation of engineered micro pancreata (EMPs) composed of naked islets (Io) and micro-scaffolds. These EMPs will be used instead to deliver substantial levels of glucose-regulated insulin secretion over long time period.
4. AltuCell | Treatment for Type 2 Diabetes
AltuCell, has published in the journal Xenotransplantation on September 2016, the Calafiore group has transplanted microencapsulated porcine Sertoli cells into the subcutaneous fat of 30 type 2 diabetic-prone obese mice. Inquisitively, 60% of the treated mice had controlled glucose level and demonstrated normal glucose tolerance tests. The remaining 40% “failures” all showed improvements as assessed by reduced HbA1c levels. Control mice remained diabetic.
5. NextCell Pharma AB- Sweden
In July 2017, NextCell Pharma submitted application to the Medical Products Agency for a clinical trial in autoimmune diabetes with its stem cell product ProTrans. Protrans is serene of stem cells derived from the umbilical cord tissue and intended for use in the treatment of inflammatory and autoimmune diseases.
More recently, NextCell Pharma AB announced on September 5, 2017, that its clinical trial application for ProTrans™ had been granted by the Ethics Committee. The clinical trial is designed to evaluate the safety of ProTrans™, as well as its ability to positively affect endogenous insulin production in adult Type 1 Diabetes patients.
6. Osiris Therapeutics- Columbia, MD, US
The company is exploring the potential usage of their “Prochymal cell therapy” for numerous conditions, as well as the diabetes. Phase II clinical trial, the evaluation of efficacy and safety was completed in 2014 for the treatment of Type 1 Diabetes. Prochymal is an adult human mesenchymal stem cell (MSC) product that possibly will adjourn the development of type 1 diabetes by preserving beta cell function, and therefore, insulin production. The physiognomies and biological action of Prochymal, laterally with a virtuous safety profile in human trials have suggested that Prochymal can be a good candidate for addressing unmet medical need in diabetic treatment.
7. Mesoblast- Australia
The company is discovering safety, efficacy and feasibility to use their “human mesenchymal progenitor cells (MPC)” products for treating Type 2 Diabetes. The results of preclinical trials suggested that, when a dose of MPCs were injected into diabetic mice, there was a subsequent increase in the level of insulin in blood and thus reducing the blood glucose levels.
Healthcare Market Research